(3R)-2-aminooctadecane-1,3-diol | 3102-56-5

• 物质功能分类: 生物化工 - 中草药成分
• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (3R)-2-aminooctadecane-1,3-diol
• CAS: 3102-56-5
• 化学式: C₁₈H₃₉NO₂
• 分子量: 301.5
• InChiKey: OTKJDMGTUTTYMP-QRWMCTBCSA-N

物化性质

• 熔点：
  70-72°C
• 沸点：
  446.2±25.0 °C(Predicted)
• 密度：
  0.927±0.06 g/cm3(Predicted)
• 溶解度：
  氯仿/甲醇(9:1)：20 mg/mL，澄清，无色至淡黄色

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  21
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• WGK Germany：
  3
• 海关编码：
  2922199090

文献信息

• Pharmaceutical formulations employing short-chain sphingolipids and their use
  申请人：Veldman J. Robert

  公开号：US20070082855A1

  公开（公告）日：2007-04-12

  This invention pertains to pharmaceutical formulations which comprise (i) a drug (e.g., an amphiphilic drug) (e.g., an anthracycline) (e.g., doxorubicin) and (ii) a short-chain sphingolipid (e.g., a short-chain glycosphingolipid or a short-chain sphingomyelin) (e.g., N-octanoyl-glucosylceramide, referred to as C 8 -GlcCer) (e.g., N-hexanoyl-sphingomyelin, referred to herein as C 6 -SM), and which provide improved drug delivery and efficacy. The short-chain sphingolipidis selected from compounds of the following formula: wherein: R 1 is independently: an O-linked saccharide group; or an O-linked polyhydric alcohol group; or: R 1 is independently: an O-linked (optionally N-(C 1-4 alkyl)-substituted amino)-C 1-6 alkyl-phosphate group; or an O-linked (polyhydric alcohol-substituted)-C 1-6 alkyl-phosphate group; R 2 is independently C 3-9 alkyl, and is independently unsubstituted or substituted; R 3 is independently C 7-19 alkyl, and is independently unsubstituted or substituted; R 4 is independently —H, —OH, or —O—C 1-4 alkyl; R N is independently —H or C 1-4 alkyl; the bond marked with an alpha (α) is independently a single bond or a double bond; if the bond marked with an alpha (α) is a double bond, then R 5 is —H; if the bond marked with an alpha (α) is a single bond, then R 5 is —H or —OH; the carbon atom marked (*) is independently in an R-configuration or an S-configuration; the carbon atom marked (**) is independently in an R-configuration or an S-configuration; and pharmaceutically acceptable salts, solvates, esters, ethers, chemically protected forms thereof. In one embodiment, the pharmaceutical formulation is a liposomal pharmaceutical formulation prepared using a mixture of lipids comprising, at least, vesicle-forming lipids (e.g., phospholipids) (e.g., phosphatidylcholines) (e.g., fully hydrogenated soy phosphatidylcholine (HSPC)) (e.g., dipalmitoyl-phosphatidylcholine (DPPC)) and said short-chain sphingolipid, and optionally cholesterol and optionally a vesicle-forming lipid which is derivatized with a polymer chain (e.g., a phosphatidylethanolamine (PE) which is derivatized with polyethyleneglycol (PEG)) (e.g., N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (MPEG2000-DSPE). The present invention also pertains to methods for the preparation and use of such formulations.
• METHODS OF INCREASING THE BIOAVAILABILITY AND/OR CELLULAR UPDATE OF DRUGS
  申请人：VELDMAN Robert J.

  公开号：US20110150984A1

  公开（公告）日：2011-06-23

  This invention pertains to methods of increasing the bioavailability and/or cellular uptake of an amphiphilic drug when administered parenterally, which method comprises the step of parenterally co-administering the drug with a short-chain sphingolipid as described herein.
• ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID
  申请人：INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES

  公开号：US20210015767A1

  公开（公告）日：2021-01-21

  The invention provides an artificially synthesized single sphingosine lipid and use of delivering a nucleic acid thereof. More particularly, the invention provides Use or method for delivering a nucleic acid to a cell or a subject using a compound of Formula (I), a stereoisomer or a pharmaceutical acceptable salt thereof, or a combination comprising a compound of Formula (I), a stereoisomer or a pharmaceutical acceptable salt thereof,
• US7915227B2
  申请人：——

  公开号：US7915227B2

  公开（公告）日：2011-03-29
• [EN] SELECTIVE INHIBITORS AND ALLOSTERIC ACTIVATORS OF SPHINGOSINE KINASE<br/>[FR] INHIBITEURS SÉLECTIFS ET ACTIVATEURS ALLOSTÉRIQUES DE LA SPHINGOSINE KINASE
  申请人：UNIV CITY NEW YORK RES FOUND

  公开号：WO2014118556A2

  公开（公告）日：2014-08-07

  Sphingosine 1-phosphate (S1P) is involved in hyper-proliferative diseases, such as cancer and vascular remodeling in pulmonary arterial hypertension. Inhibitors of sphingosine kinase 1 and 2 (SK1 and SK2), which catalyze the synthesis of S1P, may be useful anti- proliferative agents. We have synthesized a series of sphingosine-based inhibitors of SK and SK2. Also provided in this invention are compounds that activate SK1 which can be used in diseases such as fibrosis, where intracellular S1P is anti-fibrotic.